Abstract
Innate responses to microbes are mediated in large part by toll-like receptors (TLRs), which recognise a diverse range of molecules produced by viruses, bacteria and fungi. Great effort has been directed towards translating this knowledge into the development of new therapies for a wide spectrum of diseases, including infectious, malignant, autoimmune and allergic diseases. This review will provide a brief update on completed, ongoing and planned clinical trials of TLR ligand-based therapies for the treatment of diseases in humans.
Publication types
-
Research Support, N.I.H., Extramural
-
Review
MeSH terms
-
Adjuvants, Immunologic / therapeutic use
-
Autoimmune Diseases / drug therapy
-
Autoimmune Diseases / immunology
-
Communicable Diseases / drug therapy
-
Communicable Diseases / immunology
-
Humans
-
Hypersensitivity / drug therapy
-
Hypersensitivity / immunology
-
Immunity, Innate / immunology
-
Immunotherapy / methods
-
Ligands
-
Neoplasms / drug therapy
-
Neoplasms / immunology
-
Sepsis / drug therapy
-
Sepsis / immunology
-
Toll-Like Receptors / agonists
-
Toll-Like Receptors / antagonists & inhibitors
-
Toll-Like Receptors / immunology*
Substances
-
Adjuvants, Immunologic
-
Ligands
-
Toll-Like Receptors